- Home
- CATO vs APLT Comparison
CATO vs APLT Comparison
Compare CATO & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- APLT
- Stock Information
- Founded
- CATO 1946
- APLT 2016
- Country
- CATO United States
- APLT United States
- Employees
- CATO N/A
- APLT N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- CATO Consumer Discretionary
- APLT Health Care
- Exchange
- CATO Nasdaq
- APLT Nasdaq
- Market Cap
- CATO 57.6M
- APLT 62.9M
- IPO Year
- CATO N/A
- APLT 2019
- Fundamental
- Price
- CATO $2.85
- APLT $0.43
- Analyst Decision
- CATO
- APLT Buy
- Analyst Count
- CATO 0
- APLT 6
- Target Price
- CATO N/A
- APLT $6.10
- AVG Volume (30 Days)
- CATO 42.3K
- APLT 1.2M
- Earning Date
- CATO 08-21-2025
- APLT 08-19-2025
- Dividend Yield
- CATO 5.96%
- APLT N/A
- EPS Growth
- CATO N/A
- APLT N/A
- EPS
- CATO N/A
- APLT N/A
- Revenue
- CATO $642,949,000.00
- APLT $265,000.00
- Revenue This Year
- CATO N/A
- APLT $415.60
- Revenue Next Year
- CATO N/A
- APLT $1,323.96
- P/E Ratio
- CATO N/A
- APLT N/A
- Revenue Growth
- CATO N/A
- APLT N/A
- 52 Week Low
- CATO $2.19
- APLT $0.30
- 52 Week High
- CATO $6.70
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- CATO 47.88
- APLT 47.89
- Support Level
- CATO $2.72
- APLT $0.40
- Resistance Level
- CATO $2.98
- APLT $0.48
- Average True Range (ATR)
- CATO 0.21
- APLT 0.04
- MACD
- CATO -0.02
- APLT -0.01
- Stochastic Oscillator
- CATO 25.00
- APLT 17.08
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.